Shares of Ruby Tuesday, Inc. (RT) have gained more than 10% ahead of its fiscal fourth-quarter report, which is scheduled for later today.

This Zacks #1 Rank Top Performer is moving on much heavier-than-normal volume of 1.2 million, compared to the daily average of 636,000.

RT is 1 of 6 companies from the Retail-Restaurants industry on today's Zacks #1 Rank List. (There are 224 stocks on the list today.) The other 5 companies are Bob Evans Farms, Inc. (BOBE), Cracker Barrel Old Country Store, Inc. (CBRL), DineEquity, Inc. (DIN), O'Charley's, Inc. (CHUX) and The Steak n Shake Company (SNS).

Reporting Later Today

RT is scheduled to report after the bell today. At the moment, analysts expect 20 cents per share in its fiscal fourth-quarter. In the year-ago quarter, RT earned 27 cents.

The consensus

...

For Immediate Release

Chicago, IL - June 1, 2009 - Zacks.com releases the latest Industry Outlook. Today's interview is with senior analyst Grant Zeng, who talks about the Biotech Industry, including Myriad Genetics (MYGN), Onyx Pharmaceuticals Inc. (ONXX), AMAG Pharmaceuticals Inc. (AMAG), Dendreon (DNDN) and 3SBio Inc. (SSRX).

A synopsis of today's Industry Outlook is presented below. The full article can be read at http://at.zacks.com/?id=2678.

Our best picks at this point include Myriad Genetics (MYGN), Onyx Pharmaceuticals Inc. (ONXX) and AMAG Pharmaceuticals Inc. (AMAG), Dendreon (DNDN) and 3SBio Inc. (SSRX). We have different reasons for a BUY rating for each of the four companies, but all of these companies have one thing in common -- strong balance sheets, which eliminates immediate financing needs.

Both MYGN

...

OVERVIEW

The Biotech industry as a whole continues to underperform the market so far this year. As of May 26, 2009, Both the AMEX Biotech Index and the broader NASDAQ Biotech Index declined 6.8% (AMEX Biotech has 20 biotech companies while NASDAQ Biotech Index includes over 130 component companies), while the Dow Jones Biotech Index declined 3% (which includes 33 companies).

At the same time, both the NASDAQ Composite and S&P 500 have achieved positive returns. NASDAQ has made a gain of 11% as of 5/26/09 and the S&P 500 has gained 0.8%, while the Dow Jones Industrials reached a negative 3.5% return.

This constitutes a sharp contrast with last year when the Biotech industry as a whole achieved much better performance than the market. In 2008, all three biotech indices outperformed all three major market indices by a large margin. The three major indices declined as much as over 40% (34%, 41%

...

OVERVIEWThe Biotech industry as a whole continues to underperform the market so far this year. As of May 26, 2009, Both the AMEX Biotech Index and the broader NASDAQ Biotech Index declined 6.8% (AMEX Biotech has 20 biotech companies while NASDAQ Biotech Index includes over 130 component companies), while the Dow Jones Biotech Index declined 3% (which includes 33 companies).At the same time, both the NASDAQ Composite and S&P 500 have achieved positive returns. NASDAQ has made a gain of 11% as of 5/26/09 and the S&P 500 has gained 0.8%, while the Dow Jones Industrials reached a negative 3.5% return.This constitutes a sharp contrast with last year when the Biotech industry as a whole achieved much better performance than the market. In 2008, all three biotech indices outperformed all three major market indices by a large margin. The three major indices declined ...

In a Schedule 14A proxy statement filed on May 20, 2009 Merck & Co. (MRK) disclosed that it had received notification from Johnson & Johnson's (JNJ) Centocor subsidiary of its intention to terminate, through arbitration, the distribution agreement with Schering-Plough Corp (SGP) for Remicade and golimumab (Simponi). As we detailed in prior reports and blogs, we had expected some sort of challenge from J&J, so the recent news comes as no surprise.In March 2009 Merck and Co. and Schering-Plough announced a merger agreement whereby the companies would combine in a deal currently valued at approximately $48.8 billion. The deal was structured as a "reverse-merger" with Schering-Plough being the surviving entity. Merck believes that the "reverse-merger" structure will avoid triggering a change-of-control provision in Schering-Plough's agreement with J&J relative to rights to Remicade and golimumab.J&J discovered both compounds and licensed ex-U.S. marketing rights ...

Asian markets declined Monday amid concerns the outbreak of swine flu in North America will hurt the recovery in the global economy.  Shares of airlines and transport companies declined as concerned investors cut risky positions.  Travel and leisure stocks also took a hit.  The Hang Seng index in Hong Kong slumped 418.43 points, or 2.7%, to 14,840.42.  South Korea's Kospi lost 1.1% to close at 1,339.83.  The Nikkei Stock Average in Japan edged up 18.35 points, or 0.2%, to close at 8,726.34.  In Mexico, the swine flu death toll rose to 103 as governments around the world rushed to control the spread of a possible flu pandemic.

On Friday, U.S. markets advanced with the Nasdaq ending higher for the seventh straight week, driven by several better-than-expected tech quarterly earnings reports.  The DJIA and S&P 500 ended the week slightly lower, trimming six-weeks of gains. On the DJIA, shares edged

...

div style=”text-align: justify;”Natixis Bleichroeder is out with a pretty nasty downgrade on span style=”font-weight: bold;”Medicis (NYSE:MRX)/span taking their rating to Hold from Buy noting the entire market seems to be against Medicis and it’s fairly easy to see why –span style=”color: rgb(255, 0, 0); font-weight: bold;” if they lose Solodyn to generics, they would likely start losing money./spanbr /br /And yesterday’s news that the FDA had approved Impax’s generic the day before sent the stock into a nosedive. There is almost a universal view that the next wave of generics will be right behind and it will render Impax’s inability to launch because of the settlement with Medicis moot. And with this headwind it is hard to see the stock outperforming from here. But a large unanswered question is why only Impax? They were the only generic not sued and therefore there is no ambiguity that there would be no …

By Keith Fitz-Gerald In a Money Morning commentary back in April, I suggested that while we’d hit a new market bottom, we almost certainly hadn’t hit the market bottom. So have we now? That’s tough to say, although three seemingly unrelated bits of data suggest the ultimate market bottom may be lower still, meaning investors aren’t out of the woods, yet. Let’s take a look: Since 1990, there have been 13 declines of 10% or more in the Standard & Poor’s 500 Index. And while each drop of this magnitude tends to precede a rally of six months or more, an ultimate market bottom typically hasn’t been established until we’ve seen an average reading of 36.3 in the Chicago Board Options Exchange Volatility Index - usually referred to as the VIX Index. Generally regarded as a ...

Back in April I talked up Cash America International (NYSE:CSH) because with the market on edge and American's strapped for cash, it just made sense. America's largest pawn shop and payday loan service is on fire today after raising Q2 estimates.  There's no reason why the trend can't continue. This stock was a defensive play in April and still is in July.  Shares of CSH are up 15% today after raising their Q2 08 earnings outlook above analyst estimates on higher revenue from its pawn business and lower-than-anticipated ...

Steve Reeves' return on his portfolio is at a positive 8.73% as of May 29th, 2008.  Reeves is our OTC specialist and never pulls the trigger on a stock that costs more than $5.  Review his portfolio of stocks and decide for yourself if you'd like to become a subscriber. Fellow Masters, my articles and stock recommendations are now available on www.WallStNewsletters.com. I look for undervalued securities and the cheaper the price the better.  OTC stocks are my favorite hunting grounds and I never pull the trigger on a stock that costs more than $5 and is worth holding for at least ...